Jazz Pharmaceuticals PLC Zanidatamab HERIZON-GEA-01 Investor Webcast Transcript

Jan 09, 2026 / 02:30PM GMT

Release Date Price: $161.13 (+0.55%)

Transcript 8-K

Operator

Good morning and welcome to the Zanidatamab HERIZON-GEA-01 investor call and webcast. (Operator Instruction) As a reminder, this conference call is being recorded. I would now like to turn the call over to Renee Gala, President and Chief Executive Officer of Jazz Pharmaceuticals. Thank you. Please go ahead.

Renee Gala

Jazz Pharmaceuticals PLC - President, Chief Executive Officer, Director

Thank you, operator. Good morning, everyone. My name is Renee Gala, President and CEO of Jazz Pharmaceuticals. Thank you for joining us. Before I begin, please note that today's five presentation accompanying this webcast and call is available on the investors section of our website.

Yesterday, we presented groundbreaking data from the phase 3 HERIZON-GEA-01 clinical trial assessing Zanidatamab in combination with chemotherapy with or without tislelizumab. In first line HER2 positive GEA patients. At the American Society of Clinical Oncology, Gastrointestinal Cancer symposium. We have the privilege of being joined today by Dr Geoffrey Ku, associate attending

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.